21 related articles for article (PubMed ID: 8555646)
1. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of saffron-derived carotenoids in prostate cancer cell models.
Festuccia C; Mancini A; Gravina GL; Scarsella L; Llorens S; Alonso GL; Tatone C; Di Cesare E; Jannini EA; Lenzi A; D'Alessandro AM; Carmona M
Biomed Res Int; 2014; 2014():135048. PubMed ID: 24900952
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
Gondek T; Szajewski M; Szefel J; Aleksandrowicz-Wrona E; Skrzypczak-Jankun E; Jankun J; Lysiak-Szydlowska W
Biomed Res Int; 2014; 2014():102478. PubMed ID: 24783193
[TBL] [Abstract][Full Text] [Related]
4. Associations of IgG N-linked oligosaccharide chains and proteases in sera of prostate cancer patients with and without alpha2-macroglobulin deficiency.
Kanoh Y; Egawa S; Baba S; Akahoshi T
J Clin Lab Anal; 2009; 23(2):125-31. PubMed ID: 19288446
[TBL] [Abstract][Full Text] [Related]
5. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.
Angelucci A; D'Ascenzo S; Festuccia C; Gravina GL; Bologna M; Dolo V; Pavan A
Clin Exp Metastasis; 2000; 18(2):163-70. PubMed ID: 11235992
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats.
Nakanishi H; Takeuchi S; Kato K; Shimizu S; Kobayashi K; Tatematsu M; Shirai T
Jpn J Cancer Res; 1996 Dec; 87(12):1218-26. PubMed ID: 9045956
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
9. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
10. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
12. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]